Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Obesity as a consequence of acquired anatomical hypothalamic damage as evidenced by BMI ≥30 and ≤60 kg/m2~* Greater than 6 months post-treatment, including chemotherapy, surgery or radiation with resulting injury to the hypothalamus and/or the pituitary~* Stable body weight for at least 3 months~* Type 2 diabetes mellitus is allowed~Exclusion Criteria:~* Males taking gonadotropin replacement therapy (LH/FSH)~* Subjects who are planning any fertility treatment within 6 months of study participation~* Use of weight loss agents, including herbal medications, in the past 3 months~* Current or anticipated chronic use of narcotics or opiates~* History of severe psychiatric disorders~* Type 1 diabetes mellitus~* Metabolic disorders or genetic disorders linked to obesity~* History of any bariatric surgery~* Participation in any clinical study with an investigational drug or device within the 3 months prior to enrollment in this study~* Blood loss or donation \>500 mL within the past 3 months~* Females who are pregnant, nursing, intend to become pregnant during the study or any males who plan to father/conceive a child within 6 months after completion of study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ZGN-440 sterile diluent (Type: PLACEBO_COMPARATOR): Subjects will receive placebo twice weekly subcutaneous injections for 4 weeks.
- ZGN-440 for injectable suspension (Type: EXPERIMENTAL): Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).